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Background: The purpose of the present study was to demonstrate that post-operative morbidity (PM)
associated with resections of hilar cholangiocarcinoma (HCCA) is associated with short- and long-term
patient survival.
Methods: Between 1998 and 2008, 51 patients with a median age of 64 years underwent resection for
HCCA at a single institution. Associations between survival and clinicopathologic factors, including peri-
and post-operative variables, were studied using univariate and multivariate models.
Results: Seventy-six per cent of patients underwent major hepatectomy with resection of the extrahe-
patic bile ducts. The 30- and 90-day operative mortality was 10% and 12%. The overall incidence of PM
was 69%, with 68% of all PM as major (Clavien grades III–V). No difference in operative blood loss or
peri-operative transfusion rates was observed for patients with major vs. minor or no PM. Patients with
major PM received adjuvant chemotherapy less frequently than patients with minor or no complications
29% vs. 52%, P = 0.15. The 1-, 3- and 5-year overall (OS) and disease-specific survival (DSS) rates for
all patients were 65%, 36%, 29% and 77%, 46%, 35%, respectively. Using univariate and multivariate
analysis, margin status (27% R1), nodal metastasis (35% N1) and major PM were associated with OS and
DSS, P < 0.01. Major PM was an independent factor associated with decreased OS and DSS [hazard ratio
(HR) = 3.6 and 2.8, respectively, P < 0.05]. The median DSS for patients with major PM was 14 months
compared with 40 months for patients who experienced minor or no PM, P < 0.01.
Conclusion: Extensive operations for HCCA can produce substantial post-operative morbidity. In addi-
tion to causing early mortality, major post-operative complications are associated with decreased long-
term cancer-specific survival after resection of HCCA.
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Introduction
Adenocarcinomas arising from the extrahepatic biliary tree are
uncommon malignancies. Hilar cholangiocarcinomas (HCCA)
represent less than 2% of all gastrointestinal cancers, and few
institutions have expertise in their management.1,2 Furthermore,
tumours located at the hepatic hilum challenge the capability of
even high-resolution pre-operative imaging techniques to deter-
mine the local extent of disease accurately. Potential curative
therapy for hilar cholangiocarcinoma requires complete operative
resection, but more than half of patients with HCCA will not be
candidates for resection as a result of the presence of advanced
disease, either metastatic or locoregional spread, at the time of
clinical presentation.3–7
The median survival of patients with unresectable HCCA is
typically less than 12 months, but, for patients with resected
tumours, it is in the order of 3 years.5,6,8 As a result of the influence
of the surgical resection margin on long-term outcome, more
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aggressive operative approaches towards HCCA have been
adopted and have advocated en bloc hepatectomy with resection
of the extrahepatic biliary tree.9–14 An extensive operation to
accomplish a margin-negative resection for HCCA poses a major
risk for substantial post-operative morbidity and mortality, espe-
cially in patients with pre-existing medical conditions.6,10,14–17
Several studies have reported the negative consequences of
medical co-morbidities for overall survival of patients with cancer
even when these are considered before the introduction of
treatment-related adverse events.3,18–20
Operative complications have a negative impact on both short-
and long-term outcomes, including cancer-specific survival, for
patients with various cancers, e.g. colorectal, hepatocellular and
oesophageal.21–27 The effects of post-operative morbidity on long-
term outcome after resection of HCCA have not been published
widely. The purpose of this single-institution study was to evalu-
ate the specific complications that are encountered during and
after the operative management of HCCA and to determine their
influence on long-term survival.
Methods
Patients
Between January 1998 and December 2008, 51 consecutive
patients underwent operative resection for HCCA at Indiana Uni-
versity Hospital and Methodist Hospital, Indianapolis, IN. Per-
mission to study these patients was obtained from the Indiana
University School of Medicine Institutional Review and Privacy
Board according to the institutional policy for protected health
information. Patients were identified from the institutions’ clini-
cal database. Patients’ demographic, clinical, operative, pathologi-
cal and follow-up data were studied retrospectively. The diagnosis
of HCCA was verified by a concordant diagnosis contained within
the pre-operative radiology report, operative note and pathology
description. Patients who underwent liver transplantation as part
of treatment for HCCA were excluded.
Clinical data
All clinical data were obtained from the patient electronic medical
record system which contains all pre-, peri- and post-operative
information. Pre-operative body mass index (BMI) and age-
adjusted Charlson co-morbidity index (CCI) were calculated for
all patients.28 Pre-operative serum biochemical values, including
total bilirubin, creatinine and albumin, were recorded closest to
the date of operation. Pre-operative biliary drainage was labelled
as percutaneous for drainage procedures which involved percuta-
neous transhepatic cholangiography (PTC) or endoscopic for
patients who underwent endoscopic retrograde cholangiography
(ERC) for biliary stenting. Pre-operative portal vein embolization
was not performed for any patient.
In the present study, all operations for HCCA involved resec-
tion of the extrahepatic biliary tree. Hepatopancreatoduodenec-
tomy was not performed for any patient. Hepatectomy was
typically performed en bloc with resection of the biliary tree.
Continuity and extent of portal lymphadenectomy could not be
ascertained for all cases. Major hepatectomy was defined as a
hepatectomy involving resection of at least three liver segments.
All biliary reconstructions involved a Roux-en-Y cholangio- or
hepaticojejunostomy.
Tumour specimens from both hospitals were analysed histo-
pathologically at a centralized pathology laboratory. Tumour his-
tology was graded as well, moderately or poorly differentiated.
Major vascular invasion involving the portal vein and/or hepatic
artery was recorded from the operative note or pathology report.
Lymph node status was determined from the number of positive
and negative lymph nodes recorded in the final pathology report.
Operative resection margins were determined from the operative
notes and pathology reports and were categorized as R0 (negative
microscopic margin), R1 (positive microscopic margin) or R2
(grossly involved margin). Appropriate TNM staging was deter-
mined for all HCCA patients according to the AJCC guidelines
(6th Edition) for bile duct carcinomas.29
Early post-operative outcomes were analysed for each patient
and included type and timing of post-operative complications,
length of hospital stay and 30- and 90-day operative mortality.
Post-operative complications were graded according to the
Clavien grading system.30 Patients were categorized into three
groups according to the highest level of post-operative complica-
tions: none, minor (Clavien grade I or II) or major (Clavien III, IV,
or V) complication.
Adjuvant systemic chemotherapy or combinational chemorad-
iotherapy was recorded; however, details of adjuvant therapy,
including type and duration, were not available for all patients,
especially for those treated outside of Indiana University and
Methodist Hospitals. Follow-up time was calculated from the date
of operation to the date of last clinical encounter captured by the
electronic medical record system or the date of death when it
occurred. Dates of death were confirmed with the Social Security
Database. Data regarding disease recurrence were extracted from
either medical records or radiology reports. Overall survival (OS),
disease-specific survival (DSS) and recurrence-free survival (RFS)
were calculated based on the survivorship status at last follow-up.
Location of tumour recurrence was specified as local (liver
margin, bile duct, or anastomotic), regional (lymph node), and/or
distant (extra-marginal liver or extrahepatic). Time to recurrence
was calculated between the date of operation and the first docu-
mentation of tumour recurrence.
Statistics
Statistical analyses were performed using SPSS Software Version
17.0 for Windows (SPSS Inc., Chicago, IL, USA) and Microsoft
Excel 2007. Categorical variables were compared using a c2-test.
Continuous variables were expressed as median with range or
mean  standard error of mean (SEM). Continuous variables
were compared using an independent samples Mann–Whitney
U-test or Student’s t-test as appropriate. Survival probabilities
were estimated using the Kaplan–Meier method and compared
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with a log-rank test. Mortality, resulting from operative compli-
cations, was not excluded from survival analyses. Multivariable
analyses of survival were performed with a Cox regression
analysis.
Results
Patient, disease and treatment characteristics
Fifty-one patients with a median age of 64 years (range, 40–87)
underwent resection of HCCA. Sixteen patients (31%) did not
experience a post-operative complication, and 11 patients (22%)
experienced only minor (grade I or II) complications. These
patients were grouped together and compared with 24 patients
(47%) who experienced major (grades III–V) post-operative
complications. Table 1 summarizes the clinical, operative and
pathological differences between the two groups of patients. The
only significant objective differences between the two groups of
patients pre-operatively were albumin level and type of biliary
drainage procedure. Twenty-two (92%) of the patients in the
major complication group underwent a major hepatectomy as
part of operative resection; whereas, 17 (63%) patients with no or
minor postoperative complications underwent a hepatectomy (P
= 0.02).
Post-operative morbidity and mortality
The 30- and 90-day mortality rates were 10% and 12%, respec-
tively. The median number of complications for patients who died
in the early (<30 days) post-operative period was 4 (range, 2–6).
The median number of complications was 1 (range, 1–4) for
patients who experienced only minor complications vs. 2 (range,
1–6) for the major complication group. Major post-operative
complications were associated with a significantly longer length of
hospital stay. Median length of stay for the 24 patients in the major
complication group was 17 days (range, 6–62 days) compared
with 10 days for the 27 patients with no or minor complications
(range, 6–18 days), P < 0.01.
The types and frequencies of post-operative morbidity after
resection of HCCA are listed in Table 2. The most common minor
complications included cholangitis, bacteraemia and superficial
wound infection. The most common major complications were
an intra-abdominal abscess requiring percutaneous drainage with
radiographic guidance, post-operative bleeding and bile leak
requiring intervention (either percutaneous biloma drainage or
transhepatic stenting). Three patients required early reoperation
to manage major post-operative complications [bleeding (2),
portal vein thrombosis]. Post-operative liver failure, defined at
our institution as a total serum bilirubin greater than 10 mg/dl
accompanied by coagulopathy on or after post-operative day five,
was apparent in four patients. Multiorgan failure was present in
two of these patients and resulted in death in both cases.
Survival analysis
The median follow-up for all patients was 19 months (0–106
months). For survivors, the median follow-up was 28 months
(19–106) with no significant difference between patients grouped
according to complication grade. There were no differences in OS
or DSS for patients with no post-operative morbidity or minor
complications only. The estimated 1-, 3- and 5-year OS for
patients who experienced no or minor post-operative morbidity
were 81%, 56%, and 38%, respectively. The actuarial 3- and 5-year
DSS for this same group of patients were 51% and 40%, respec-
tively. Comparatively, these survival rates were statistically better
than those for patients who experienced major post-operative
morbidity (Fig. 1). Unlike the OS plots, post-operative mortality
did not serve as an event for DSS estimations. After excluding
patients who died within 90 days of operation (n = 6), there was
still a significant difference in survival between patients who expe-
rienced no or minor post-operative morbidity (median DSS = 40
months) and those with major, non-fatal complications (median
DSS = 14 months), P = 0.05.
Tumour recurrence was detected in 14 patients (27%) during
the follow-up period. The median time to recurrence for all
patients was 18 months; 35 months for patients with no or
minor post-operative complications compared with 10 months
for the major complications group, P = 0.15. The most common
location for tumour recurrence was the distant liver (i.e. outside
the liver margin) and occurred in 10 patients. One local recur-
rence involved the hepaticojejunostomy, four involved regional
lymph nodes and four distant extrahepatic recurrences were
observed.
Multivariable analysis of survival
Post-operative morbidity, resection margin status, pre-operative
Charlson comorbidity index, pre-operative biliary drainage pro-
cedure and lymph node status were associated with OS and DSS
using univariate analysis. These factors were included in a propor-
tional hazards model to identify independent predictors of
outcome, namely OS and DSS. Using multivariable analysis, major
post-operative morbidity was associated with a significant decline
in OS (Table 3) as well as DSS [not shown, hazard ratio (HR) =
2.8, 95% confidence interval (CI) = 1.3–6.5; P = 0.04]. The other
factors associated with a significantly worse OS (Table 3) and DSS
were R1 resection and pre-operative Charlson comorbidity index.
The DSS HR for an R1 resection was 4.3, P = 0.003 and that for a
pre-operative Charlson index 4 was 4.8, P = 0.007. The median
number of lymph nodes examined for all patients was four. Posi-
tive lymph node status was an independent factor associated with
OS but not with DSS.
Discussion
In order to accomplish complete tumour clearance, the operative
management of HCCA typically requires resection of the extra-
hepatic biliary tree in continuity with a large portion of the liver
including the caudate. These procedures have substantial potential
for major post-operative complications including liver failure.
Extensive hepatobiliary operations also require technically chal-
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Table 1 Complications after resection for hilar cholangiocarcinoma (HCCA) differences in patient, operative, and pathological characteristics
No or minor complicationsa Major complicationsa P-value
Patients n = 27 n = 24
Ageb 63 y (40–78) 65 y (44–87) 0.14
Gender 0.97
Male 19 (70%) 17 (71%)
Female 8 (30%) 7 (29%)
Body mass indexb 26 kg/m2 (21–35) 24.5 kg/m2 (18–32) 0.19
Charlson comorbidity indexb 4 (2–7) 4 (2–9) 0.39
Pre-operative serum valuesc
Albumin 3.4  0.1 g/dL 2.8  0.1 g/dL 0.01
Total bilirubin 4.1  0.9 mg/dL 4.4  0.8 mg/dL 0.81
Creatinine 1.0  0.04 mg/dl 0.9  0.04 mg/dL 0.29
Pre-operative biliary drainage 0.02
Percutaneous 8 (30%) 13 (54%)
Endoscopic 15 (55%) 9 (38%)
None 4 (15%) 2 (8%)
Operative details
Major hepatectomy 17 (63%) 22 (92%) 0.02
Right hepatectomy 7 (26%) 9 (38%) 0.05
Left hepatectomy 10 (37%) 13 (54%) 0.05
Trisectionectomy 1 (4%) 3 (12%) 0.33
Caudate resection 1 (4%) 3 (12%) 0.33
Portal vein resection 1 (4%) 2 (8%) 0.59
Operative blood lossb 900 mL (100–6000) 1250 mL (400–4500) 0.42
Margin status 0.38
R0 21 (78%) 16 (67%)
R1 6 (22%) 8 (33%)
Adjuvant therapy 0.15
Chemotherapy 14 (52%) 7 (29%)
Chemoradiotherapy 3 (11%) 1 (4%)
Tumour histological grade 0.63
Well differentiated 14 (52%) 12 (50%)
Moderate/poorly differentiated 13 (48%) 12 (50%)
Histological invasion 0.12
Lymphovascular 5 (19%) 1 (4%)
Perineural 12 (44%) 14 (58%)
Both 2 (7%) 4 (17%)
None 8 (30%) 5 (21%)
Lymph node status 0.68
Positive 11 (41%) 7 (29%)
Negative 13 (48%) 14 (58%)
Unknown 3 (11%) 3 (13%)
Major vascular invasion 1 (4%) 3 (12%) 0.62
AJCC stage (6th ed.) 0.48
IA 2 (7%) 4 (17%)
IB 3 (11%) 2 (8%)
IIA 8 (30%) 11 (46%)
IIB 13 (48%) 7 (29%)
III 1 (4%) 0
aMinor complications: Clavien grade I, II; major complications: grade III–V.
bExpressed as median (range).
cExpressed as mean (SEM).
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lenging reconstructions of the bile ducts which pose risks
for bile leakage and intra-abdominal sepsis. Our single institution
experience highlights the objective complications which are
encountered after extensive operations for HCCA. Seventy-six per
cent of the patients in the present study underwent a major hepa-
tectomy; however, unlike other recently published series, the
caudate resection and trisectionectomy rates were under 10%.31–33
Pre-operative portal vein embolization was not utilized, but nearly
90% of patients received pre-operative biliary drainage. The R0
resection rate of 73% is consistent with other published
reports from highly experienced centers.12,34–36 A comparison of
outcomes for patients who underwent resection of HCCA
before or after the year 2003, when a formal hepatopancreatobil-
iary unit was organized at our institution, did not reveal
major differences between the two eras with the exception that
patients were more likely to undergo hepatectomy and hepatec-
tomy with en bloc caudate resection in the recent era (i.e. years
2003 to 2008). Despite better pre-operative imaging to improve
patient selection combined with advancements in operative tech-
niques and post-operative care, there has been no significant
decrease in post-operative morbidity or mortality over time
at our institution. This finding suggests that more aggressive
operative approaches to patients with advanced, higher-risk
tumours offset the benefits of improved peri- and post-operative
care for HCCA.
Comparing patients who did or did not experience major
post-operative complications or mortality, we did not unveil
many objective differences between these two groups of patients
except for the extent of hepatectomy and type of pre-operative
biliary drainage. Pre-operative percutaneous drainage and major
hepatectomy were both associated with more post-operative
morbidity. On the other hand, operative blood loss and peri-
operative transfusion rate, which are often interpreted as surro-
gates for extent of tumour burden and extent of resection, did
not correlate with early or late post-operative outcomes. The
negative impact of peri-operative blood transfusion on survival
has been published for patients undergoing hepatectomy
for hepatocellular carcinoma and colorectal metastases;
however, controversy remains with regards to a true cause and
effect relationship.22,24,37
Although hypoalbuminaemia did not correlate with poorer
long-term outcomes, pre-operative albumin levels were signifi-
cantly lower in the patients who developed major complications.
Malnutrition is a major concern for patients scheduled to
undergo complex abdominal operations, and nutritional assess-
ment should be a routine component of pre-operative evalua-
tion. A nutrition risk index has been developed that stratifies
patients into groups according to the severity of malnutrition.38
This index is calculated from the albumin level and deficit of
lean body mass. Severe degrees of malnutrition are associated
with post-operative complication rates over 50% and mortality
rates approaching 20%.35 Our centre currently employs a full-
time nutritionist who is dedicated solely to the pre-operative
clinical setting.
Since its inception, the Charlson comorbidity index (CCI) has
provided validated prognostic information for predicting mid-
and long-term survival for cancer patients.19,28,39,40 One potential
deficiency of the CCI for predicting survival after resection of
HCCA is the formulary dependence on chronic medical diseases
(e.g. diabetes, renal failure, etc.) which could become
somewhat irrelevant in the setting of aggressive cancers. In the
present study, CCI correlated with post-operative complications
and with long-term survival on multivariable analysis,
which considered multiple factors reflective of cancer treatment.
Fernandez-Ruiz et al. also reported that CCI has a negative
impact on survival for patients with extrahepatic cholangiocar-
cinoma treated either operatively or medically.41 Given
its easy application, CCI can be implemented in the risk strati-
fication process for patients being considered for resection of
HCCA.
The majority of patients with HCCA present with various
degrees of liver dysfunction related to obstructive cholestasis.
Many experienced centres have adopted treatment algorithms that
include routine preoperative biliary drainage procedures, either
percutaneous or endoscopic, while some centres use biliary drain-
age selectively with or without portal vein embolization after con-
sideration of the status and volume of the future liver
remnant.6,17,42,43 In this retrospective analysis, we were not able to
Table 2 Post-operative complications types and frequency
Complication type No. patients (%)
Minor complications 11 (22%)
Cholangitis 5 (10%)
Bacteremia 4 (8%)
Superficial wound infection 4 (8%)
Pleural effusion 3 (6%)
DVT/PE 2 (4%)
Bile leak not requiring intervention 1 (2%)
Pancreatitis 1 (2%)
Pneumonia 1 (2%)
Urinary tract infection 1 (2%)
Major complications 24 (47%)
Intra-abdominal abscess treated with drainage 11 (22%)
Death (90 day) 6 (12%)
Death (30 day) 5 (10%)
Bile leak treated with intervention 5 (10%)
Post-operative bleeding 4 (8%)
Organ failure 3 (6%)
Multiple (including hepatic) 2 (4%)
Hepatic only 2 (4%)
Cardiovascular ischaemia or dysrhythmia 1 (2%)
Fascial dehiscence 1 (2%)
Portal vein thrombosis 1 (2%)
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determine how patients were selected for pre-operative biliary
drainage. Pre-operative cholangitis has been reported as an inde-
pendent predictor of post-operative morbidity.3,6 In our study,
however, we were not able to determine accurately how many
patients had clinical cholangitis before operative resection. The
use of pre-operative endoscopic biliary drainage was associated
with an improvement in complication rates and even long-term
survival, but this finding could represent a confounding bias with
less extensive hilar tumours. It is possible that reliable biliary
decompression with ERC poses less risk for pre-operative
cholangitis.
In this series, the overall complication rate was 69% with over
two-thirds categorized as major morbidity according to the
Clavien grading system.30 Whereas, many experienced centres
have reported operative mortality rates less than 10% and post-
operative morbidity rates of approximately 50%, our 90-day mor-
tality rate was 12% and post-operative complications occurred in
69% of patients.6,12,15,33,42 The most common major post-operative
complication was intra-abdominal sepsis which in many cases
resulted from difficult bile leaks. In addition to the short-term
impact of septic complications on operative mortality, several
studies have demonstrated a correlation between long-term
outcomes after curative resections of solid tumours and
post-operative sepsis.21–23,44 Infection and sepsis potentiate proin-
flammatory cytokine cascades including tumour necrosis factor-a
and interleukins 1, 6, and 8. These immune modulators can affect
the function and regulation of natural killer cells, cytotoxic
T-lymphocytes and antigen-presenting cells.45–47 Hypothetically,
occult micrometastases may progress rapidly during brief and
prolonged periods of relative immunosuppression resulting from
systemic infection. Thus, the future development and clinical use
of immunomodulators may play a role in offsetting the potentially
detrimental oncologic effects of the systemic inflammatory
responses during periods of post-operative sepsis and organ dys-
function.
A major goal for the operative management of HCCA
must focus on reducing peri- and post-operative complications.
Sano and colleagues at the National Cancer Center Hospital in
Tokyo, Japan performed 102 consecutive hepatobiliary resections
for perihilar cholangiocarcinoma without a single case of
operative mortality and with a major complication rate under
7%.6 These impressive results and others have served
as a benchmark for many centres who treat patients with
cholangiocarcinoma.10,48
Based on the significant impact of existing pre-operative
co-morbidities on long-term outcomes, patient selection must
consider both cancer- and patient-related factors. Despite the
limitations of a retrospective design and small sample size, the
results of the present study show a clear association between post-
operative morbidity and short-term mortality and long-term
cancer-specific survival for patients undergoing resection for
HCCA. Operations for hilar bile duct tumours must be conducted
safely with minimal post-operative mortality and acceptable mor-
bidity. Multiple parameters must be considered to improve short-
and long-term outcomes in patients with HCCA. Proper patient
selection with judicious use of pre-operative biliary drainage and
portal vein embolization is crucial. Performance of a safe opera-
tion with minimal blood loss and careful anatomic reconstruction
is important for reducing post-operative complications. Avoid-
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Figure 1 (a) Actuarial overall (OS) and (b) disease-specific survival (DSS) for patients undergoing resection for hilar cholangiocarcinoma
(HCCA). Patients are categorized into two groups according to post-operative complications: none or minor (grade I or II, n = 27) and major
(grade III–V, n = 24). Proportion surviving is shown over time (months)
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HR 95% CI P-value
Complication 0.008, 0.04, 0.15
None or minor 27 (53%) 36 m (81,56,38%) 40 m (85,51,40%)
Major 24 (47%) 9 m (46,29,19%) 14 m (64,41,27%) 3.58 1.47–8.27 0.005
Resection margin status 0.01, 0.02, 0.009
R0 37 (72%) 30 m (70,53,43%) NR (81,55,55%)
R1 14 (28%) 12 m (50,19,0%) 15 m (64,24,0%) 4.23 1.89–9.52 <0.01
Charlson comorbidity index 0.006, 0.05, 0.02
Low (<4) 18 (35%) 40 m (94,69,43%) 40 m (94,58,47%)
High (4) 33 (65%) 10 m (49,30,20%) 16 m (64,39,39%) 7.36 2.68–12.12 <0.01
Pre-operative biliary drainage 0.03, 0.01, 0.01
Endoscopic 24 (47%) 36 m (75,69,40%) NR (86,62,62%)
Percutaneous 21 (41%) 13 m (52,23,16%) 14 m (65,29,20%) 0.57
None 6 (12%) 16 m (67,33,33%) 19 m (80,40,40%) 0.71
LN status 0.03, 0.006, 0.03
Negative 27 (53%) 40 m (70,51,46%) NR (79,58,51%)
Positive 18 (35%) 30 m (67,44,22%) 36 m (86,36,36%) 1.27 1.10–5.45 0.05
Not assessed 6 (12%) 7 m (33,20,20%) 12 m (50,35,35%) 5.95 2.10–16.67 0.001
Tumour histological grade 0.11, 0.21, 0.24
Well differentiated 26 (51%) 40 m NR
Mod/poorly diff 25 (49%) 15 m 16 m
Pre-operative bilirubin 0.45, 0.49, 0.75
<10 mg/dl 44 (86%) 16 m 36 m
10 mg/dl 7 (14%) 15 m NR
Pre-operative albumin 0.19, 0.37, 0.26
3.0 g/dl 23 (45%) 13 m 36 m
>3.0 g/dl 28 (55%) 30 m NR
Operation 0.42, 0.10, 0.01
Hepatectomy 39 (76%) 30 m 40 m
No hepatectomy 12 (24%) 15 m 15 m
EBL 0.27, 0.25, 0.52
<1000 ml 30 (59%) 16 m 16 m
1000 ml 21 (41%) 16 m 36 m
Transfusion (RBC peri-operative)
Yes 26 (51%) 19 m 40 m 0.37, 0.30, 0.06
No 25 (49%) 13 m 16 m
Adjuvant therapy 0.24, 0.65, 0.14
Yes 21 (41%) 36 m 36 m
No 30 (59%) 13 m NR
OS, overall survival; DSS, disease-specific survival; RFS, recurrence-free survival.
*Log-rank test.
NR = not reached.
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gible to receive more effective adjuvant therapies which should
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